<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
	<ui>1556-276X-7-436</ui>
	<ji>1556-276X</ji>
	<fm>
		<dochead>Nano Express</dochead>
		<bibl>
			<title>
				<p>Calpain inhibitor nanocrystals prepared using Nano Spray Dryer B-90</p>
			</title>
			<aug>
				<au id="A1" ca="yes"><snm>Baba</snm><fnm>Koichi</fnm><insr iid="I1"/><email>koichi.baba@ophthal.med.osaka-u.ac.jp</email></au>
				<au id="A2"><snm>Nishida</snm><fnm>Kohji</fnm><insr iid="I1"/><email>knishida@ophthal.med.osaka-u.ac.jp</email></au>
			</aug>
			<insg>
				<ins id="I1"><p>Department of Ophthalmology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan</p></ins>
			</insg>
			<source>Nanoscale Research Letters</source>
			<section><title><p>Regular submissions</p></title></section><issn>1556-276X</issn>
			<pubdate>2012</pubdate>
			<volume>7</volume>
			<issue>1</issue>
			<fpage>436</fpage>
			<url>http://www.nanoscalereslett.com/content/7/1/436</url>
			<xrefbib><pubidlist><pubid idtype="doi">10.1186/1556-276X-7-436</pubid><pubid idtype="pmpid">22863139</pubid></pubidlist></xrefbib>
		</bibl>
		<history><rec><date><day>6</day><month>6</month><year>2012</year></date></rec><acc><date><day>23</day><month>7</month><year>2012</year></date></acc><pub><date><day>4</day><month>8</month><year>2012</year></date></pub></history>
		<cpyrt><year>2012</year><collab>Baba and Nishida.; licensee Springer.</collab><note>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
				<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</note></cpyrt>
		<kwdg>
			<kwd>Calpain inhibitor</kwd>
			<kwd>Drug nanocrystals</kwd>
			<kwd>Nano Spray Dryer B-90</kwd>
			<kwd>81.07.Wx</kwd>
			<kwd>81.16.-c</kwd>
		</kwdg>
		<abs>
			<sec>
				<st>
					<p>Abstract</p>
				</st>
				<p>The Nano Spray Dryer B-90 offers a new, simple, and alternative approach for the production of drug nanocrystals. Among attractive drugs, calpain inhibitor that inhibits programmed cell death &#8216;apoptosis&#8217; is a candidate for curing apoptosis-mediated intractable diseases such as Alzheimer&#8217;s disease and Parkinson&#8217;s disease. In this study, the preparation of calpain inhibitor nanocrystals using Nano Spray Dryer B-90 was demonstrated. The particle sizes were controlled by means of selecting mesh aperture sizes. The obtained average particle sizes were in the range of around 300&#8201;nm to submicron meter.</p>
			</sec>
		</abs>
	</fm>
	<bdy>
		<sec>
			<st>
				<p>Background</p>
			</st>
			<p>Using drug nanoparticles for a drug delivery system has attracted considerable attentions in the field of nanomedicine. Especially, nanoparticles with a drug filling rate of 100% including their amorphous form are called drug nanocrystals 
				<abbrgrp>
					<abbr bid="B1">1</abbr>
				</abbrgrp>. Since a nanocrystal has large surface area compared to a microparticle, the drug nanocrystal has several unique peculiarities such as its increased dissolution velocity, increased saturation velocity, and increased adhesiveness to cell membranes 
				<abbrgrp>
					<abbr bid="B2">2</abbr>
				</abbrgrp>. Additionally, drug nanocrystals are able to deliver large amount of drugs into cells and tissues at a single particle level because of their densely packed crystal structure 
				<abbrgrp>
					<abbr bid="B2">2</abbr>
				</abbrgrp>. Because of their unique physicochemical properties, recently, drug nanocrystals have been considered as a novel type of drug formulation for the drug delivery system 
				<abbrgrp>
					<abbr bid="B3">3</abbr>
				</abbrgrp>.</p>
			<p>Several approaches for preparing drug nanocrystals are classified as top-down and bottom-up procedures 
				<abbrgrp>
					<abbr bid="B4">4</abbr>
				</abbrgrp>. For the top-down procedures, techniques of milling, homogenization, and laser ablation are reported. For the bottom-up procedures, techniques of precipitation, chemical vapor, emulsion, and spray dryer are representatives. However, for the top-down procedures, all media milling processes involve high-energy input and are highly inefficient, and a considerable amount of heat is generated in these operations, making processing of thermolabile materials difficult. The contamination of milling balls that should be removed from drug dispersions by some efforts is also a problem, whereas for the bottom-up procedures, the removal of harsh solvents used for the preparation processes of drug dispersions is necessary in the precipitation technique 
				<abbrgrp>
					<abbr bid="B1">1</abbr>
				</abbrgrp>. Since the spray dryer technique takes a facile approach for preparing nanoparticles, which carries out spraying, evaporating the solvent-dissolved drug, and collecting drug particles, numerous drugs can be candidate for nanoparticle preparation in this technique. However, it is difficult for conventional spray dryer techniques to prepare particles with less than 2&#8201;&#956;m in size and also to collect their fine particles 
				<abbrgrp>
					<abbr bid="B5">5</abbr>
				</abbrgrp>. In other words, submicrometer-sized particles, i.e., nanoparticles, cannot be obtained using the conventional spray dryer. Recently, an advanced spray dryer technology, Nano Spray Dryer B-90, has been developed by B&#252;chi&#174; (Flawil, Switzerland) 
				<abbrgrp>
					<abbr bid="B6">6</abbr>
				</abbrgrp>. The functions of piezoelectrically driven vibrating mesh and electrostatic particle collector realize the successful preparation and collection of nanoparticles. The different mesh aperture sizes create different sizes of nanoparticles. Currently, drug-encapsulated polymeric nanoparticles 
				<abbrgrp>
					<abbr bid="B7">7</abbr>
				</abbrgrp>, protein nanoparticles 
				<abbrgrp>
					<abbr bid="B8">8</abbr>
				</abbrgrp>, and lithium carbonate (Li<sub>2</sub>CO<sub>3</sub>) hollow spheres used in lithium batteries 
				<abbrgrp>
					<abbr bid="B9">9</abbr>
				</abbrgrp> have been successfully prepared using Nano Spray Dryer B-90.</p>
			<p>Recently, our interest is focused on preparing calpain inhibitor nanocrystals. Calpain inhibitors inhibit the calpain activity, resulting in reducing the calpain-meditated apoptosis 
				<abbrgrp>
					<abbr bid="B10">10</abbr>
				</abbrgrp>. Several kinds of calpain inhibitors have been synthesized such as leupeptin which improves motor neuron survival in rat embryos and calpain inhibitor VI (SJA6017) and calpain inhibitor XI [Z-L-Abu-CONH(CH2)3-morpholine] which are used for protecting both retinal and cortical neurons, respectively, against ischemia-induced damage 
				<abbrgrp>
					<abbr bid="B10">10</abbr>
				</abbrgrp>. Furthermore, calpain inhibitors are currently one of the most attractive drugs for curing intractable diseases such as Alzheimer&#8217;s disease and Parkinson&#8217;s disease 
				<abbrgrp>
					<abbr bid="B10">10</abbr>
				</abbrgrp>. In this research, we demonstrated the preparation of calpain inhibitor nanocrystals in powder conditions using Nano Spray Dryer B-90. The calpain inhibitor drugs selected were calpain inhibitor I (Figure&#8201;
				<figr fid="F1">1</figr>a) 
				<abbrgrp>
					<abbr bid="B11">11</abbr>
				</abbrgrp> and ((1&#8201;S)-1-((((1&#8201;S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester (SNJ-1945; Figure&#8201;
				<figr fid="F1">1</figr>b) 
				<abbrgrp>
					<abbr bid="B12">12</abbr>
				</abbrgrp>. Since it is known that the mesh aperture size significantly controls the resulting particle size 
				<abbrgrp>
					<abbr bid="B13">13</abbr>
				</abbrgrp>, we investigated the relationship between mesh aperture size and particle size of drugs. Additionally, we briefly noted the effects of the concentration of dissolved drug solution, inlet temperature, and gas flow rate on the resulting particle size, especially targeting SNJ-1945 nanocrystals. </p>
			<fig id="F1"><title><p>Figure 1</p></title><caption><p>Chemical structures of calpain inhibitor I (a) and SNJ-1945 (b)</p></caption><text>
   <p>
      <b>Chemical structures of calpain inhibitor I (a) and SNJ-1945 (b).</b>
   </p>
</text><graphic file="1556-276X-7-436-1"/></fig>
		</sec>
		<sec>
			<st>
				<p>Methods</p>
			</st>
			<p>The calpain inhibitor I and ethanol (99.5%&#8201;<it>v</it>/<it>v</it>) were purchased from Wako Pure Chemical Industries (Osaka-shi, Osaka, Japan). The calpain inhibitor SNJ-1945 was kindly provided by Senju Pharmaceutical Co., Ltd. (Kobe-shi, Hyogo, Japan). Each drug was dissolved in ethanol (5&#8201;mg/10&#8201;ml). Then, each ethanol-dissolved drug solution was used for preparing each nanocrystal using Nano Spray Dryer B-90 (B&#252;chi&#174;). A schematic image of Nano Spray Dryer B-90 is illustrated in Figure&#8201;
				<figr fid="F2">2</figr>. Briefly, the drying gas, which is heated up to the setting inlet temperature, flows into the drying chamber, and then the gas exits from the spray dryer passing through the clearing filter at the bottom. The inlet temperature and outlet temperature are shown as <it>T</it>
				<sub>in</sub> and <it>T</it>
				<sub>out</sub>, respectively. The operating conditions for the experiments were kept constant at <it>T</it>
				<sub>in</sub>&#8201;=&#8201;50&#176;C, <it>T</it>
				<sub>out</sub>&#8201;=&#8201;35&#176;C, feed rates of 25&#8201;ml/h, and a drying gas flow rate of 100&#8201;L/min. Spray mesh aperture sizes of 4.0, 5.5, and 7.0&#8201;&#956;m were used in this experiment. Finally, the resulting nanocrystal powders were collected using a rubber spatula. The morphology and size of collected particles were observed by scanning electron microscopy (SEM; JEOL-6510LA, Akishima-shi, Tokyo, Japan). The average size and particle size distribution were calculated by means of counting more than 300 particles from the obtained SEM images.</p>
			<fig id="F2"><title><p>Figure 2</p></title><caption><p>Schematic image of Nano Spray Dryer B-90</p></caption><text>
   <p>
      <b>Schematic image of Nano Spray Dryer B-90.</b>
   </p>
</text><graphic file="1556-276X-7-436-2"/></fig>
		</sec>
		<sec>
			<st>
				<p>Results and discussion</p>
			</st>
			<p>The ethanol-dissolved drug solution was fed to the spray head by pumping. The solution was atomized by piezoelectrically driven mesh vibration in a small spray cap, and then millions of precisely sized droplets per second with a narrow distribution were ejected by the vibrating actuator driven at around 60&#8201;kHz. The extremely fine droplets were dried to become solid particles while passing through the chamber, and then these particles, which were electrostatically charged by dry gases of N<sub>2</sub> and CO<sub>2</sub>, were collected by the electrode. The collected particles using the rubber spatula were observed by SEM. The morphology of each calpain inhibitor nanocrystal was sphere-like regardless of mesh aperture sizes of 4.0, 5.5, and 7.0&#8201;&#956;m (Figures&#8201;
				<figr fid="F3">3</figr> and 
				<figr fid="F4">4</figr>). On the other hand, their particle sizes were associated with the mesh aperture sizes. For the calpain inhibitor I nanocrystals, the average particle sizes with their size distribution were 378&#8201;&#177;&#8201;132, 527&#8201;&#177; 284, and 813&#8201;&#177;&#8201;484&#8201;nm against mesh aperture sizes of 4.0, 5.5, and 7.0&#8201;&#956;m, respectively (Figure&#8201;
				<figr fid="F5">5</figr>). For the SNJ-1945 nanocrystals, the average particle sizes with their size distribution were 418&#8201;&#177;&#8201;138, 605&#8201;&#177;&#8201;369, and 845&#8201;&#177;&#8201;567&#8201;nm against mesh aperture sizes of 4.0, 5.5, and 7.0&#8201;&#956;m, respectively (Figure&#8201;
				<figr fid="F6">6</figr>). For both cases of calpain inhibitor I and SNJ-1945 nanocrystals, the average particle size as well as their size-distribution width relating to particle polydispersity became small and narrow with decreasing mesh aperture sizes, respectively. The validity of these results is supported by previous reports that the different mesh aperture sizes resulted in making different sizes with size-distribution widths of particles, e.g., average particle size and size-distribution width decreased with decreasing mesh aperture size 
				<abbrgrp>
					<abbr bid="B13">13</abbr>
				</abbrgrp>. This is because the small mesh aperture size (e.g., 4.0&#8201;&#956;m) tends to generate small-sized droplets of the ethanol-dissolved drug solution, which results in creating small-sized particles with narrow size-distribution widths, compared to utilizing the large mesh aperture size (e.g., 7.0&#8201;&#956;m). We revealed that the selection of mesh aperture sizes controlled the particle sizes of calpain inhibitor I and SNJ-1945 nanocrystals. </p>
			<fig id="F3"><title><p>Figure 3</p></title><caption><p>SEM images of calpain inhibitor I nanocrystals.</p></caption><text>
   <p><b>SEM images of calpain inhibitor I nanocrystals.</b> The nanocrystals were prepared using mesh with aperture sizes of 4.0 (<b>a</b>), 5.5 (<b>b</b>), and 7.0&#8201;&#956;m (<b>c</b>).</p>
</text><graphic file="1556-276X-7-436-3"/></fig>
			<fig id="F4"><title><p>Figure 4</p></title><caption><p>SEM images of SNJ-1945 nanocrystals.</p></caption><text>
   <p><b>SEM images of SNJ-1945 nanocrystals.</b> The nanocrystals were prepared using mesh with aperture sizes of 4.0 (<b>a)</b>, 5.5 (<b>b</b>), and 7.0&#8201;&#956;m (<b>c</b>).</p>
</text><graphic file="1556-276X-7-436-4"/></fig>
			<fig id="F5"><title><p>Figure 5</p></title><caption><p>Average sizes with their size distribution of calpain inhibitor I nanocrystals.</p></caption><text>
   <p><b>Average sizes with their size distribution of calpain inhibitor I nanocrystals.</b> The used mesh aperture sizes were 4.0 (<b>a</b>), 5.5 (<b>b</b>), and 7.0&#8201;&#956;m (<b>c</b>). &#8216;<it>n</it>&#8217; represents the number of counted particles.</p>
</text><graphic file="1556-276X-7-436-5"/></fig>
			<fig id="F6"><title><p>Figure 6</p></title><caption><p>Average sizes with their size distribution of SNJ-1945 nanocrystals.</p></caption><text>
   <p><b>Average sizes with their size distribution of SNJ-1945 nanocrystals.</b> The used mesh aperture sizes were 4.0 (<b>a</b>), 5.5 (<b>b</b>), and 7.0&#8201;&#956;m (<b>c</b>). &#8216;<it>n</it>&#8217; represents the number of counted particles.</p>
</text><graphic file="1556-276X-7-436-6"/></fig>
			<p>We also investigated the effects of the experimental conditions relating to the concentration of ethanol-dissolved drug solution, <it>T</it>
				<sub>in</sub>, and gas flow rate on the resulting particle size, which were compared with those of the standard sample of SNJ-1945 nanocrystals. The standard sample of SNJ-1945 nanocrystals (418&#8201;&#177;&#8201;138&#8201;nm in size) was prepared with the following experimental conditions: concentration&#8201;=&#8201;5&#8201;mg/10&#8201;ml, <it>T</it>
				<sub>in</sub>&#8201;=&#8201;50&#176;C, gas flow rate&#8201;=&#8201;100&#8201;L/min, and mesh aperture size&#8201;=&#8201;4.0&#8201;&#956;m (see the data of the standard sample in Figures&#8201;
				<figr fid="F4">4</figr>a and 
				<figr fid="F6">6</figr>a, and case I in Table&#8201;
				<tblr tid="T1">1</tblr>). It was revealed that the concentration significantly affected the particle size, namely when the concentration increased tenfold (50&#8201;mg/10&#8201;ml), the particle size increased almost twice compared to the effect of utilizing the concentration (5&#8201;mg/10&#8201;ml) of the standard sample (cases I and II in Table&#8201;
				<tblr tid="T1">1</tblr>). The image of the particles obtained by SEM observation is shown in Figure&#8201;
				<figr fid="F7">7</figr>a. The average particle size and their size distribution was 994&#8201;&#177;&#8201;360&#8201;nm (Figure&#8201;
				<figr fid="F8">8</figr>a). On the other hand, the conditions of high <it>T</it>
				<sub>in</sub> (100&#176;C) and high gas flow rate (150&#8201;L/min) did not significantly affect the particle size compared to the effect of utilizing high concentration of 50&#8201;mg/10&#8201;ml (cases I to IV in Table&#8201;
				<tblr tid="T1">1</tblr>). The images of the particles obtained by SEM observation at the conditions of <it>T</it>
				<sub>in</sub>&#8201;=&#8201;100&#176;C and gas flow rate&#8201;=&#8201;150&#8201;L/min are shown in Figure&#8201;
				<figr fid="F7">7</figr>b,c, respectively. The average particle size and their size distribution at the conditions of <it>T</it>
				<sub>in</sub>&#8201;=&#8201;100&#176;C and gas flow rate&#8201;=&#8201;150&#8201;L/min were 515&#8201;&#177; 197 and 536&#8201;&#177;&#8201;230&#8201;nm, respectively (Figure&#8201;
				<figr fid="F8">8</figr>b,c). These obtained results seemed to be reasonable when considering previous reports 
				<abbrgrp>
					<abbr bid="B13">13</abbr>
					<abbr bid="B14">14</abbr>
				</abbrgrp>, namely the particle size was significantly affected by the concentration of ethanol-dissolved drug solution, but not significantly by <it>T</it>
				<sub>in</sub> and gas flow rate. More detailed experimental conditions related to the concentration of dissolved drug solution, temperature, and gas flow rate, which will affect particle formation, will be investigated as future works including several kinds of calpain inhibitor nanocrystals. </p>
			<table id="T1">
				<title>
					<p>Table 1</p>
				</title>
				<caption>
					<p>
						<b>Particle size and size distribution of SNJ-1945 nanocrystals prepared at different experimental conditions</b>
					</p>
				</caption>
				<tgroup align="left" cols="5">
					<colspec align="left" colname="c1" colnum="1" colwidth="1*"/>
					<colspec align="center" colname="c2" colnum="2" colwidth="1*"/>
					<colspec align="center" colname="c3" colnum="3" colwidth="1*"/>
					<colspec align="center" colname="c4" colnum="4" colwidth="1*"/>
					<colspec align="center" colname="c5" colnum="5" colwidth="1*"/>
					<thead valign="top">
						<row rowsep="1">
							<entry colname="c1" morerows="1">
								<p>
									<b>Experimental conditions</b>
								</p>
							</entry>
							<entry align="center" colname="c2" nameend="c5" namest="c2">
								<p>
									<b>Samples</b>
								</p>
							</entry>
						</row>
						<row rowsep="1">
							<entry align="center" colname="c2">
								<p>
									<b>Case I</b>
								</p>
							</entry>
							<entry align="center" colname="c3">
								<p>
									<b>Case II</b>
								</p>
							</entry>
							<entry align="center" colname="c4">
								<p>
									<b>Case III</b>
								</p>
							</entry>
							<entry align="center" colname="c5">
								<p>
									<b>Case IV</b>
								</p>
							</entry>
						</row>
					</thead>
					<tfoot>
						<p>The mesh aperture size used was 4.0&#8201;&#956;m.</p>
					</tfoot>
					<tbody valign="top">
						<row>
							<entry colname="c1">
								<p>Concentration (mg/ml)</p>
							</entry>
							<entry align="center" colname="c2">
								<p>5:10</p>
							</entry>
							<entry align="center" colname="c3">
								<p>50:10</p>
							</entry>
							<entry align="center" colname="c4">
								<p>5:10</p>
							</entry>
							<entry align="center" colname="c5">
								<p>5:10</p>
							</entry>
						</row>
						<row>
							<entry colname="c1">
								<p>
									<it>T</it>
									<sub>in</sub> (&#176;C)</p>
							</entry>
							<entry align="center" colname="c2">
								<p>50</p>
							</entry>
							<entry align="center" colname="c3">
								<p>50</p>
							</entry>
							<entry align="center" colname="c4">
								<p>100</p>
							</entry>
							<entry align="center" colname="c5">
								<p>50</p>
							</entry>
						</row>
						<row>
							<entry colname="c1">
								<p>Flow rate (L/min)</p>
							</entry>
							<entry align="center" colname="c2">
								<p>100</p>
							</entry>
							<entry align="center" colname="c3">
								<p>100</p>
							</entry>
							<entry align="center" colname="c4">
								<p>100</p>
							</entry>
							<entry align="center" colname="c5">
								<p>150</p>
							</entry>
						</row>
						<row rowsep="1">
							<entry colname="c1">
								<p>Particle size and size distribution (nm)</p>
							</entry>
							<entry align="center" colname="c2">
								<p>418&#8201;&#177;&#8201;138</p>
							</entry>
							<entry align="center" colname="c3">
								<p>994&#8201;&#177;&#8201;360</p>
							</entry>
							<entry align="center" colname="c4">
								<p>515&#8201;&#177;&#8201;197</p>
							</entry>
							<entry align="center" colname="c5">
								<p>536&#8201;&#177;&#8201;230</p>
							</entry>
						</row>
					</tbody>
				</tgroup>
			</table>
			<fig id="F7"><title><p>Figure 7</p></title><caption><p>SEM images of SNJ-1945 nanocrystals.</p></caption><text>
   <p><b>SEM images of SNJ-1945 nanocrystals.</b> The nanocrystals were prepared using mesh with aperture size of 4.0&#8201;&#956;m at different experimental conditions, especially focusing on concentration (<b>a</b>), <it>T</it><sub>in</sub> (<b>b</b>), and gas flow rate (<b>c</b>).</p>
</text><graphic file="1556-276X-7-436-7"/></fig>
			<fig id="F8"><title><p>Figure 8</p></title><caption><p>Average sizes with their size distribution of SNJ-1945 nanocrystals.</p></caption><text>
   <p><b>Average sizes with their size distribution of SNJ-1945 nanocrystals.</b> The nanocrystals were prepared using mesh with aperture size of 4.0&#8201;&#956;m at different experimental conditions, especially focusing on concentration (<b>a</b>), <it>T</it><sub>in</sub> (<b>b</b>), and gas flow rate (<b>c</b>). &#8216;<it>n</it>&#8217; represents the number of counted particles.</p>
</text><graphic file="1556-276X-7-436-8"/></fig>
		</sec>
		<sec>
			<st>
				<p>Conclusions</p>
			</st>
			<p>We succeeded in preparing size-controlled calpain inhibitor nanocrystals using Nano Spray Dryer B-90. To the best of our knowledge, this is the first time to prepare calpain inhibitor nanocrystals. The particle sizes were associated with the mesh aperture sizes, namely when the mesh aperture sizes decreased, the particle sizes decreased. The concentration of ethanol-dissolved drug solution significantly affected the particle size. Calpain inhibitors will be a promising drug for curing intractable diseases such as Alzheimer&#8217;s disease and Parkinson&#8217;s disease. Therefore, utilizing the calpain-inhibitor-nanocrystal-based drug delivery system targeting such intractable diseases will be quite attractive topics in the near future, and thus our fundamental findings of preparing calpain inhibitor nanocrystals in this research are noteworthy. We are also investigating the preparation of water dispersion of calpain inhibitor nanocrystals. This nanocrystal water dispersion will act as attractive nanocrystal-based eye drops for the treatment of ophthalmic disorders such as Fuchs&#8217; endothelial dystrophy of the cornea in the near future.</p>
		</sec>
		<sec>
			<st>
				<p>Competing interests</p>
			</st>
			<p>The authors declare that they have no competing interests.</p>
		</sec>
		<sec>
			<st>
				<p>Authors&#8217; contributions</p>
			</st>
			<p>KB contributed to the conception of the study, carried out all the experiments, and drafted the manuscript. KN contributed to the interpretation of data and revised the manuscript. Both authors read and approved the final manuscript.</p>
		</sec>
		<sec>
			<st>
				<p>Authors&#8217; information</p>
			</st>
			<p>KB is a specially appointed associate professor and KN is a professor and a medical doctor at the Department of Ophthalmology, Osaka University Graduate School of Medicine, Japan.</p>
		</sec>
	</bdy>
	<bm>
		<ack>
			<sec>
				<st>
					<p>Acknowledgements</p>
				</st>
				<p>This study was partially supported by Health and Labour Science Research Grants for Research on Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan and a Challenging Exploratory Research (No. 23650287) and Grant-in-Aid for Young Scientists (A) (No. 24680054) from the Japan Society for the Promotion of Science. We thank Senju Pharmaceutical Co., Ltd. for kindly providing calpain inhibitor SNJ-1945 and Dr. Tadayoshi Egusa for his technical supports of nanocrystal preparation and SEM observation.</p>
			</sec>
		</ack>
		<refgrp><bibl id="B1"><title><p>Nanocrystal technology, drug delivery and clinical applications</p></title><aug><au><snm>Junghanns</snm><fnm>JUAH</fnm></au><au><snm>Muller</snm><fnm>RH</fnm></au></aug><source>Int J Nanomed</source><pubdate>2008</pubdate><volume>3</volume><issue>3</issue><fpage>295</fpage><lpage>309</lpage></bibl><bibl id="B2"><title><p>State of the art of nanocrystals - special features, production, nanotoxicology aspects and intracellular delivery</p></title><aug><au><snm>Muller</snm><fnm>RH</fnm></au><au><snm>Gohla</snm><fnm>S</fnm></au><au><snm>Keck</snm><fnm>CM</fnm></au></aug><source>Eur J Pharm Biopharm</source><pubdate>2011</pubdate><volume>78</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.ejpb.2011.01.007</pubid><pubid idtype="pmpid" link="fulltext">21266197</pubid></pubidlist></xrefbib></bibl><bibl id="B3"><title><p>New method for delivering a hydrophobic drug for photodynamic therapy using pure nanocrystal form of the drug</p></title><aug><au><snm>Baba</snm><fnm>K</fnm></au><au><snm>Pudavar</snm><fnm>HE</fnm></au><au><snm>Roy</snm><fnm>I</fnm></au><au><snm>Ohulchanskyy</snm><fnm>TY</fnm></au><au><snm>Chen</snm><fnm>YH</fnm></au><au><snm>Pandey</snm><fnm>RK</fnm></au><au><snm>Prasad</snm><fnm>PN</fnm></au></aug><source>Mol Pharm</source><pubdate>2007</pubdate><volume>4</volume><issue>2</issue><fpage>289</fpage><lpage>297</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1021/mp060117f</pubid><pubid idtype="pmcid">2667689</pubid><pubid idtype="pmpid" link="fulltext">17266331</pubid></pubidlist></xrefbib></bibl><bibl id="B4"><title><p>Drug nanocrystals: their physicochemical properties and production technologies</p></title><aug><au><snm>Baba</snm><fnm>K</fnm></au><au><snm>Nishida</snm><fnm>K</fnm></au></aug><source>Recent Patents on Nanomedicine</source><pubdate>2011</pubdate><volume>1</volume><issue>2</issue><fpage>123</fpage><lpage>129</lpage></bibl><bibl id="B5"><title><p>Statistical modeling of protein spray drying at the lab scale</p></title><aug><au><snm>Prinn</snm><fnm>KB</fnm></au><au><snm>Costantino</snm><fnm>HR</fnm></au><au><snm>Tracy</snm><fnm>M</fnm></au></aug><source>AAPS PharmSciTech</source><pubdate>2002</pubdate><volume>3</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><xrefbib><pubid idtype="doi">10.1208/pt030101</pubid></xrefbib></bibl><bibl id="B6"><title><p>The nano spray dryer B-90</p></title><aug><au><snm>Heng</snm><fnm>D</fnm></au><au><snm>Lee</snm><fnm>SH</fnm></au><au><snm>Ng</snm><fnm>WK</fnm></au><au><snm>Tan</snm><fnm>RB</fnm></au></aug><source>Expert Opin Drug Deliv</source><pubdate>2011</pubdate><volume>8</volume><issue>7</issue><fpage>965</fpage><lpage>972</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1517/17425247.2011.588206</pubid><pubid idtype="pmpid" link="fulltext">21675936</pubid></pubidlist></xrefbib></bibl><bibl id="B7"><title><p>Nano and microparticle engineering of water insoluble drugs using a novel spray-drying process</p></title><aug><au><snm>Schafroth</snm><fnm>N</fnm></au><au><snm>Arpagaus</snm><fnm>C</fnm></au><au><snm>Jadhav</snm><fnm>UY</fnm></au><au><snm>Makne</snm><fnm>S</fnm></au><au><snm>Douroumis</snm><fnm>D</fnm></au></aug><source>Colloids Surf B Biointerfaces</source><pubdate>2012</pubdate><volume>90</volume><fpage>8</fpage><lpage>15</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">22019455</pubid></xrefbib></bibl><bibl id="B8"><title><p>New insights into respirable protein powder preparation using a nano spray dryer</p></title><aug><au><snm>Burki</snm><fnm>K</fnm></au><au><snm>Jeon</snm><fnm>I</fnm></au><au><snm>Arpagaus</snm><fnm>C</fnm></au><au><snm>Betz</snm><fnm>G</fnm></au></aug><source>Int J Pharm</source><pubdate>2011</pubdate><volume>408</volume><issue>1&#8211;2</issue><fpage>248</fpage><lpage>256</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">21335078</pubid></xrefbib></bibl><bibl id="B9"><title><p>Preparation of lithium carbonate hollow spheres by spray pyrolysis</p></title><aug><au><snm>Sun</snm><fnm>YZ</fnm></au><au><snm>Song</snm><fnm>XF</fnm></au><au><snm>Wang</snm><fnm>J</fnm></au><au><snm>Yu</snm><fnm>JG</fnm></au></aug><source>Cryst Res Technol</source><pubdate>2011</pubdate><volume>46</volume><issue>2</issue><fpage>173</fpage><lpage>177</lpage><xrefbib><pubid idtype="doi">10.1002/crat.201000532</pubid></xrefbib></bibl><bibl id="B10"><title><p>Role of calpain in apoptosis</p></title><aug><au><snm>Momeni</snm><fnm>HR</fnm></au></aug><source>Cell J</source><pubdate>2011</pubdate><volume>13</volume><issue>2</issue><fpage>65</fpage><lpage>72</lpage></bibl><bibl id="B11"><title><p>Calpain activation in apoptosis</p></title><aug><au><snm>Squier</snm><fnm>MKT</fnm></au><au><snm>Miller</snm><fnm>ACK</fnm></au><au><snm>Malkinson</snm><fnm>AM</fnm></au><au><snm>Cohen</snm><fnm>JJ</fnm></au></aug><source>J Cell Physiol</source><pubdate>1994</pubdate><volume>159</volume><issue>2</issue><fpage>229</fpage><lpage>237</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1002/jcp.1041590206</pubid><pubid idtype="pmpid">8163563</pubid></pubidlist></xrefbib></bibl><bibl id="B12"><title><p>A novel calpain inhibitor, ((1&#8201;S)-1-((((1&#8201;S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester (SNJ-1945), reduces murine retinal cell death in vitro and in vivo</p></title><aug><au><snm>Shimazawa</snm><fnm>M</fnm></au><au><snm>Suemori</snm><fnm>S</fnm></au><au><snm>Inokuchi</snm><fnm>Y</fnm></au><au><snm>Matsunaga</snm><fnm>N</fnm></au><au><snm>Nakajima</snm><fnm>Y</fnm></au><au><snm>Oka</snm><fnm>T</fnm></au><au><snm>Yamamoto</snm><fnm>T</fnm></au><au><snm>Hara</snm><fnm>H</fnm></au></aug><source>J Pharmacol Exp Ther</source><pubdate>2010</pubdate><volume>332</volume><issue>2</issue><fpage>380</fpage><lpage>387</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1124/jpet.109.156612</pubid><pubid idtype="pmpid" link="fulltext">19910537</pubid></pubidlist></xrefbib></bibl><bibl id="B13"><title><p>Nano spray drying: a novel method for preparing protein nanoparticles for protein therapy</p></title><aug><au><snm>Lee</snm><fnm>SH</fnm></au><au><snm>Heng</snm><fnm>D</fnm></au><au><snm>Ng</snm><fnm>WK</fnm></au><au><snm>Chan</snm><fnm>HK</fnm></au><au><snm>Tan</snm><fnm>RB</fnm></au></aug><source>Int J Pharm</source><pubdate>2011</pubdate><volume>403</volume><issue>1&#8211;2</issue><fpage>192</fpage><lpage>200</lpage><xrefbib><pubid idtype="pmpid" link="fulltext">20951781</pubid></xrefbib></bibl><bibl id="B14"><title><p>Nanoparticles by spray drying using innovative new technology: the B&#252;chi Nano Spray Dryer B-90</p></title><aug><au><snm>Li</snm><fnm>X</fnm></au><au><snm>Anton</snm><fnm>N</fnm></au><au><snm>Arpagaus</snm><fnm>C</fnm></au><au><snm>Belleteix</snm><fnm>F</fnm></au><au><snm>Vandamme</snm><fnm>TF</fnm></au></aug><source>J Control Release</source><pubdate>2010</pubdate><volume>147</volume><fpage>304</fpage><lpage>310</lpage><xrefbib><pubidlist><pubid idtype="doi">10.1016/j.jconrel.2010.07.113</pubid><pubid idtype="pmpid" link="fulltext">20659510</pubid></pubidlist></xrefbib></bibl></refgrp>
	</bm>
</art>